Caribou Biosciences (CRBU) EBIT Margin (2020 - 2025)
Caribou Biosciences (CRBU) has disclosed EBIT Margin for 6 consecutive years, with 1337.58% as the latest value for Q3 2025.
- On a quarterly basis, EBIT Margin rose 55165.0% to 1337.58% in Q3 2025 year-over-year; TTM through Sep 2025 was 1657.78%, a 21828.0% decrease, with the full-year FY2024 number at 1667.16%, down 133053.0% from a year prior.
- EBIT Margin was 1337.58% for Q3 2025 at Caribou Biosciences, up from 1783.95% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 61.84% in Q3 2023 to a low of 1893.87% in Q1 2024.
- A 5-year average of 1065.58% and a median of 881.92% in 2023 define the central range for EBIT Margin.
- Peak YoY movement for EBIT Margin: surged 74865bps in 2021, then tumbled -182739bps in 2024.
- Caribou Biosciences' EBIT Margin stood at 797.38% in 2021, then fell by -4bps to 828.22% in 2022, then decreased by -27bps to 1052.33% in 2023, then tumbled by -78bps to 1871.69% in 2024, then increased by 29bps to 1337.58% in 2025.
- Per Business Quant, the three most recent readings for CRBU's EBIT Margin are 1337.58% (Q3 2025), 1783.95% (Q2 2025), and 1871.69% (Q4 2024).